| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
1 Pulmonary and Critical Care Division, Caritas St Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA, USA
2 GlaxoSmithKline R&D, Worldwide Epidemiology Department, London, UK
3 GlaxoSmithKline R&D, Discovery Medicine Department, King of Prussia, PA, UK
Correspondence to:
Correspondence to:
Dr V M Pinto-Plata
Background: Patients with chronic obstructive pulmonary disease (COPD) have raised serum levels of C reactive protein (CRP). This may be related directly to COPD and its associated systemic inflammation or secondary to other factors such as concomitant ischaemic heart disease (IHD) or smoking status. The aim of this study was to evaluate IHD and smoking as potential causes of raised CRP levels in COPD and to test the association between inhaled corticosteroid (ICS) use and serum CRP levels.
Methods: Cross sectional analyses comparing cohorts of 88 patients with COPD, 33 smokers (S), and 38 non-smoker (NS) controls were performed. Clinical assessments included a complete medical history, pulmonary function, 6 minute walk test (6MWT), cardiopulmonary exercise test, and high sensitivity serum CRP measurements.
Results: Serum CRP levels were significantly higher in patients with COPD (5.03 (1.51) mg/l) than in controls (adjusted odds ratio 9.51; 95% confidence interval 2.97 to 30.45) but were similar in the two control groups (S: 2.02 (1.04) mg/l; NS: 2.24 (1.04) mg/l). There was no clinical or exercise evidence of unstable IHD in any of the subjects. CRP levels were lower in COPD patients treated with ICS than in those not treated (3.7 (3.0) mg/l v 6.3 (3.6) mg/l); this association was confirmed in an adjusted regression model (p<0.05).
Conclusion: CRP levels are raised in COPD patients without clinically relevant IHD and independent of cigarette smoking, and reduced in patients with COPD using ICS. CRP may be a systemic marker of the inflammatory process that occurs in patients with COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; ICS, inhaled corticosteroids; IHD, ischaemic heart disease; 6MWT, 6 minute walk test; TLC, total lung capacity; TLCO, carbon monoxide transfer factor; 
O2peak, peak oxygen consumption
Keywords: C-reactive protein; chronic obstructive pulmonary disease; ischaemic heart disease; smoking; inhaled corticosteroids; systemic inflammation; exercise capacity
Related Article
Thorax 2006 61: 1.
This article has been cited by other articles:
|
|
 |
|
  R. Jiang, G. L. Burke, P. L. Enright, A. B. Newman, H. G. Margolis, M. Cushman, R. P. Tracy, Y. Wang, R. A. Kronmal, and R. G. Barr Inflammatory Markers and Longitudinal Lung Function Decline in the Elderly Am. J. Epidemiol., August 6, 2008; (2008) kwn174v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zorzetto, E. Russi, O. Senn, M. Imboden, I. Ferrarotti, C. Tinelli, I. Campo, S. Ottaviani, R. Scabini, A. von Eckardstein, et al. SERPINA1 Gene Variants in Individuals from the General Population with Reduced {alpha}1-Antitrypsin Concentrations Clin. Chem., August 1, 2008; 54(8): 1331 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Butland, D. P. Strachan, and A. R. Rudnicka C-reactive protein, obesity, atopy and asthma symptoms in middle-aged adults Eur. Respir. J., July 1, 2008; 32(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sunyer, R. Pistelli, E. Plana, M. Andreani, F. Baldari, M. Kolz, W. Koenig, J. Pekkanen, A. Peters, and F. Forastiere Systemic inflammation, genetic susceptibility and lung function Eur. Respir. J., July 1, 2008; 32(1): 92 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahl Biomarkers for Chronic Obstructive Pulmonary Disease: Surfactant Protein D and C-Reactive Protein Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1177 - 1178. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. de Torres, V. Pinto-Plata, C. Casanova, H. Mullerova, E. Cordoba-Lanus, M. Muros de Fuentes, A. Aguirre-Jaime, and B. R. Celli C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD Chest, June 1, 2008; 133(6): 1336 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Sapey, D Bayley, A Ahmad, P Newbold, N Snell, and R A Stockley Inter-relationships between inflammatory markers in patients with stable COPD with bronchitis: intra-patient and inter-patient variability Thorax, June 1, 2008; 63(6): 493 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin, S. F. P. Man, D. D. Marciniuk, G. Ford, M. FitzGerald, E. Wong, E. York, R. R. Mainra, W. Ramesh, L. S. Melenka, et al. The Effects of Fluticasone with or without Salmeterol on Systemic Biomarkers of Inflammation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1207 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Falk, O. A. Minai, and Z. Mosenifar Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Falk, S. Kadiev, G. J. Criner, S. M. Scharf, O. A. Minai, and P. Diaz Cardiac Disease in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 543 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Chatila, B. M. Thomashow, O. A. Minai, G. J. Criner, and B. J. Make Comorbidities in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bozinovski, A. Hutchinson, M. Thompson, L. MacGregor, J. Black, E. Giannakis, A.-S. Karlsson, R. Silvestrini, D. Smallwood, R. Vlahos, et al. Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., February 1, 2008; 177(3): 269 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Han, V. V. McLaughlin, G. J. Criner, and F. J. Martinez Pulmonary Diseases and the Heart Circulation, December 18, 2007; 116(25): 2992 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ambrosino and R. Goldstein Series on comprehensive management of end-stage COPD Eur. Respir. J., November 1, 2007; 30(5): 828 - 830. [Full Text] [PDF]
|
|
|
|
|
|
V. Pinto-Plata, J. Toso, K. Lee, D. Park, J. Bilello, H. Mullerova, M. M De Souza, R. Vessey, and B. Celli Profiling serum biomarkers in patients with COPD: associations with clinical parameters Thorax, July 1, 2007; 62(7): 595 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Rabe, B. Beghe, F. Luppi, and L. M. Fabbri Update in Chronic Obstructive Pulmonary Disease 2006 Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1222 - 1232. [Full Text] [PDF]
|
|
|
|
|
|
C-G. Lofdahl, D. S. Postma, N. B. Pride, J. Boe, and A. Thoren Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD Eur. Respir. J., June 1, 2007; 29(6): 1115 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W Fogarty, S. Jones, J. R Britton, S. A Lewis, and T. M McKeever Systemic inflammation and decline in lung function in a general population: a prospective study Thorax, June 1, 2007; 62(6): 515 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cote, M. D. Zilberberg, S. H. Mody, L. J. Dordelly, and B. Celli Haemoglobin level and its clinical impact in a cohort of patients with COPD Eur. Respir. J., May 1, 2007; 29(5): 923 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dahl, J. Vestbo, P. Lange, S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 250 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D D Sin Inhaled corticosteroids and mortality in COPD. Thorax, October 1, 2006; 61(10): 918 - 918. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin and S.F. P. Man Cooling the Fire Within: Inhaled Corticosteroids and Cardiovascular Mortality in COPD. Chest, September 1, 2006; 130(3): 629 - 631. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin and S. F. P. Man Pharmacotherapy for Mortality Reduction in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, September 1, 2006; 3(7): 624 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli Predicting mortality in chronic obstructive pulmonary disease: chasing the "holy grail". Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1298 - 1299. [Full Text] [PDF]
|
|
|
|
|
|
E. F. M. Wouters The systemic face of airway diseases: the role of C-reactive protein. Eur. Respir. J., May 1, 2006; 27(5): 877 - 879. [Full Text] [PDF]
|
|
|
|
|
|
I. D. Pavord, S. S. Birring, M. Berry, R. H. Green, C. E. Brightling, and A. J. Wardlaw Multiple inflammatory hits and the pathogenesis of severe airway disease. Eur. Respir. J., May 1, 2006; 27(5): 884 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. de Torres, E. Cordoba-Lanus, C. Lopez-Aguilar, M. Muros de Fuentes, A. Montejo de Garcini, A. Aguirre-Jaime, B. R. Celli, and C. Casanova C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Eur. Respir. J., May 1, 2006; 27(5): 902 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D D Sin and S F P Man Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link? Thorax, January 1, 2006; 61(1): 1 - 3. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
